Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio 43210, USA.
J Biol Chem. 2013 Jan 11;288(2):1032-46. doi: 10.1074/jbc.M112.426957. Epub 2012 Nov 30.
Kinase/phosphatase balance governs cardiac excitability in health and disease. Although detailed mechanisms for cardiac kinase regulation are established, far less is known regarding cardiac protein phosphatase 2A (PP2A) regulation. This is largely due to the complexity of the PP2A holoenzyme structure (combinatorial assembly of three subunit enzyme from >17 subunit genes) and the inability to segregate "global" PP2A function from the activities of multiple "local" holoenzyme populations. Here we report that PP2A catalytic, regulatory, and scaffolding subunits are tightly regulated at transcriptional, translational, and post-translational levels to tune myocyte function at base line and in disease. We show that past global read-outs of cellular PP2A activity more appropriately represent the collective activity of numerous individual PP2A holoenzymes, each displaying a specific subcellular localization (dictated by select PP2A regulatory subunits) as well as local specific post-translational catalytic subunit methylation and phosphorylation events that regulate local and rapid holoenzyme assembly/disassembly (via leucine carboxymethyltransferase 1/phosphatase methylesterase 1 (LCMT-1/PME-1). We report that PP2A subunits are selectively regulated between human and animal models, across cardiac chambers, and even within specific cardiac cell types. Moreover, this regulation can be rapidly tuned in response to cellular activation. Finally, we report that global PP2A is altered in human and experimental models of heart disease, yet each pathology displays its own distinct molecular signature though specific PP2A subunit modulatory events. These new data provide an initial view into the signaling pathways that govern PP2A function in heart but also establish the first step in defining specific PP2A regulatory targets in health and disease.
激酶/磷酸酶平衡控制着心脏在健康和疾病中的兴奋性。虽然心脏激酶调节的详细机制已经确立,但对于心脏蛋白磷酸酶 2A(PP2A)的调节知之甚少。这主要是由于 PP2A 全酶结构的复杂性(由>17 个亚基基因组合的三种亚基酶的组合装配),以及无法将“全局”PP2A 功能与多个“局部”全酶群体的活性分开。在这里,我们报告 PP2A 催化、调节和支架亚基在转录、翻译和翻译后水平受到严格调节,以调节基础和疾病中的心肌功能。我们表明,过去对细胞 PP2A 活性的整体读数更恰当地代表了许多单个 PP2A 全酶的集体活性,每个全酶都显示出特定的亚细胞定位(由特定的 PP2A 调节亚基决定),以及局部特定的翻译后催化亚基甲基化和磷酸化事件,这些事件调节局部和快速的全酶组装/拆卸(通过亮氨酸羧甲基转移酶 1/磷酸酶甲硫氨酸酯酶 1(LCMT-1/PME-1)。我们报告说,PP2A 亚基在人类和动物模型、心脏腔室甚至特定的心脏细胞类型之间受到选择性调节。此外,这种调节可以快速响应细胞激活进行调整。最后,我们报告说,全球 PP2A 在人类和实验性心脏病模型中发生改变,但每种病理表现出其自身独特的分子特征,尽管存在特定的 PP2A 亚基调节事件。这些新数据提供了一个初步的视角,了解控制心脏中 PP2A 功能的信号通路,但也为在健康和疾病中定义特定的 PP2A 调节靶点迈出了第一步。